Please provide your email address to receive an email when new articles are posted on . The novel gene therapy is aimed at optogenetic vision restoration in diseases causing blindness. The Series A ...
BIO Capital continues support as founding investor, having backed Ray Therapeutics since seed funding in 2021 through Series ...
Researchers have developed an implantable artificial retina that converts near-infrared light into electrical signals, ...
Married couple Jean Bennett and Albert Maguire developed Luxturna, which helped a patient see their child’s face for the first time ...
RMAT designation enables intensified FDA engagement and potential accelerated pathways, implying preliminary clinical evidence for RTx-015 despite absent peer-reviewed efficacy details, endpoints, and ...
DALLAS, March 30, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with ...
Please provide your email address to receive an email when new articles are posted on . The trial, which included 27 participants, met its safety and efficacy endpoints at 52 weeks and 76 weeks. The ...
Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...
The Breakthrough Prize Foundation awarded researchers involved in developing gene therapies for blindness and sickle cell ...
The disease causes the gradual degeneration of light-sensitive cells in the retina, leading to the development of blind spots ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results